CAR-NK

Combotope Therapeutics and CiMaas Announce Oncology Research and License Option Agreement

cimaas_gebruiker / October 5, 2023

Collaboration for the discovery and development of innovative cancer-specific CAR-NK products is underway, leveraging Combotope Therapeutics’ proprietary Tumor Glycoform specific […]

News

CiMaas receives exclusive option for the use of high affinity antibody structures in immune cells, including CAR-NK and CAR-T cells

cimaas_gebruiker / March 30, 2023

By entering into a research collaboration with an option for an exclusive commercial license for its antibody structures (specific directed against

Scroll to Top